Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

After the Duchess of Sussex announced her American Riviera Orchard rebrand, she once again is facing accusations of ...

February 20, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, ...

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most oversold S&P 500 stocks in 2024. Strong economic growth and the prospect of declining ...